Biohaven’s Distinct Path
Taking on the turbulence of the weight loss drug sector, __Biohaven’s__ BHVN‘s CEO, __Vlad Coric__, appeared on CNBC Fast Money to discuss the bombardment of competition and the emergence of the company’s experimental obesity drug.
Unique Drug Development
Diving into uncharted waters, Biohaven revealed its venture into an obesity drug that operates differently compared to __Novo Nordisk A/S’s__ NVO and __Eli Lilly And Co’s__ LLY popular GLP-1 drugs.
The experimental obesity drug, named __taldefgrobep alfa (BHVN-2000)__, is envisioned to combat muscle loss while facilitating weight loss.
The company underscores that a significant percent of weight reduction through GLP-1 drugs accounts for muscle mass.“What we are attempting is to drive substantial weight loss sans muscle loss, a stark departure from the GLPs,” CEO Vlad Coric shared with CNBC.
Revolutionary Strategy
Biohaven is pioneering the development of taldefgrobep alfa (t-alpha), targeting myostatin to govern muscle growth.
Coric further elaborated, “By inhibiting myostatin, taldefgrobep alfa is poised to amplify lean muscle mass, kickstart resting metabolism, prompt weight loss, all while steering clear of muscle reduction.”
In October 2023, Biohaven unveiled preclinical data pointing to the capability of taldefgrobep alfa to notably curb fat mass while elevating lean mass in an obese mouse model.
Within a mouse model mirroring diet-induced obesity, untreated mice demonstrated a 31% rise in fat mass; however, taldefgrobep-treated mice exhibited a 25% surge in lean mass from baseline and a 11% drop in baseline fat in comparison to vehicle (placebo) treated mice.
Market Strategy and Future Prospects
Insulin and leptin levels exhibited consistent declines in taldefgrobep-treated mice versus the untreated cohort.
Currently in a Phase 1 trial for obesity, Taldefgrobep alfa is poised to commence a Phase 2 trial by the second quarter of 2024, __Biohaven__ stated.
__Biohaven__ anticipates assessing taldefgrobep alfa as a standalone therapy and in conjunction with GLP-1s.
The CEO noted the ascendancy of GLPs as the new standard of care for obesity, further adding, “Our aim is to showcase that Taldefgrobep alfa can stand alone against GLPs, with the added dimension of a crucial synergistic role in tandem with GLPs,” expressed Coric.
__Eli Lilly__ is also in the pursuit of a parallel product attained through the __Versanis Bio’s__ $1.925 billion transaction.
__Bimagrumab__, another myostatin inhibitor in __Eli Lilly’s__ kitty, has proposed the ability to diminish fat mass while conserving muscle mass for individuals confronted with obesity and obesity-related complexities.
Beyond obesity, taldefgrobep alfa is being groomed for __Spinal Muscular Atrophy__, a genetic neurodegenerative condition marked by progressive muscle deterioration, presently in the Phase 3 development stage with an anticipation of topline data by the latter part of 2024.
Price Action: __BHVN__ shares are flying high at 3.84% to $57.35 as of the last check on a Tuesday.
Photo via Shutterstock
